Liu J.,Chaoyang Sanhuan Cancer Hospital |
Zhang Y.,Chaoyang Sanhuan Cancer Hospital |
Qu T.,Cancer Hospital and Institute |
Shi S.,Chaoyang Sanhuan Cancer Hospital |
And 7 more authors.
Chinese Journal of Clinical Oncology | Year: 2013
Objective: This retrospective study aims to determine the efficacy of chemotherapy and improve a salvage chemotherapy agent for metastatic colorectal cancer (MCRC) after failure of treatment with irinotecan and oxaliplatin. Methods: Between January 2002 and March 2013, 37 patients with metastatic MCRC who had progressed after treatment with irinotecan and oxaliplatin were analyzed for their response rate (RR) and progression-free survival (PFS). Results: The overall RR of the 37 patients was 13.51%, with 5 cases of partial response (PR), 12 cases of disease stabilization (SD), and 20 cases of progression (PD). Compared with other chemotherapy regimens, treatment with a pemetrexed-based chemotherapy agent had a higher RR (17.64% vs. 10.00%, P=0.64) without a longer PFS (2.00 months vs. 1.63 months, HR=0.79, 95%, CI: 0.35 to 1.78, P=0.58). Compared with other chemotherapy regimens, treatment with a raltirexed-based chemotherapy agent had a higher RR (16.67% vs. 12.00%, P=0.34) without a longer PFS (1.58 months vs. 1.90 months, HR=2.24, 95%, CI: 0.98 to 5.12, P=0.06).Conclusion: In patients with MCRC after failure of treatment with irinotecan and oxaliplatin, a pemetrexed-based or raltirexed-based chemotherapy agent may beneficial during salvage treatment and is therefore worthy of further study. Source